Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis

Arthritis and Rheumatology

Volumn 66, Issue 9, 2014, Pages 2440-2449

  Huebner, Janet L ^a   Bay Jensen, Anne C ^b   Huffman, Kim M ^a   He, Yi ^b   Leeming, Diana J ^b   McDaniel, Gary E ^a   Karsdal, Morten A ^b   Kraus, Virginia B ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA C TELOPEPTIDE OF TYPE 1 COLLAGEN; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; MEDRONATE TECHNETIUM TC 99M; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ARTICULAR CARTILAGE; BONE SCINTISCANNING; BONE TURNOVER; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; JOINT CAVITY; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OSTEOPHYTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

AGED; BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN TYPE I; COLLAGEN TYPE II; DISEASE PROGRESSION; FEMALE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE;

EID: 84907388269     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38739     Document Type: Article

References (50)

1. Bailey AJ, Mansell JP, Sims TJ, Banse X. Biochemical and mechanical properties of subchondral bone in osteoarthritis. Biorheology 2004;41:349-58. (Pubitemid 39277092)
2. Garnero P, Peterfy C, Zaim S, Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005;52:2822-9. (Pubitemid 41369112)
3. Wohl GR, Shymkiw RC, Matyas JR, Kloiber R, Zernicke RF. Periarticular cancellous bone changes following anterior cruciate ligament injury. J Appl Physiol 2001;91:336-42. (Pubitemid 32574743)
4. Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong LT. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006;38:234-43. (Pubitemid 43165790)
5. Boyd SK, Matyas JR, Wohl GR, Kantzas A, Zernicke RF. Early regional adaptation of periarticular bone mineral density after anterior cruciate ligament injury. J Appl Physiol 2000;89:2359-64.
6. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011;377:2115-26.
7. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009;14:181-202.
8. Qvist P, Christiansen C, Karsdal MA, Madsen SH, Sondergaard BC, Bay-Jensen AC. Application of biochemical markers in development of drugs for treatment of osteoarthritis. Biomarkers 2010;15:1-19.
9. Dam EB, Loog M, Christiansen C, Byrjalsen I, Folkesson J, Nielsen M, et al. Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther 2009;11:R115.
10. Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002;46:3178-84. (Pubitemid 35453526)
11. Cloos PA, Lyubimova N, Solberg H, Qvist P, Christiansen C, Byrjalsen I, et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 2004;50:279-89. (Pubitemid 38877727)
12. Henriksen K, Leeming DJ, Byrjalsen I, Nielsen RH, Sorensen MG, Dziegiel MH, et al. Osteoclasts prefer aged bone. Osteoporos Int 2007;18:751-9. (Pubitemid 46684778)
13. Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, et al. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prev 2006;15:1392-5. (Pubitemid 44125298)
14. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:32-8.
15. Leeming DJ, Hegele A, Byrjalsen I, Hofmann R, Qvist P, Karsdal MA, et al. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev 2008;17:1269-76.
16. Pearle AD, Warren RF, Rodeo SA. Basic science of articular cartilage and osteoarthritis. Clin Sports Med 2005;24:1-12. (Pubitemid 43073031)
17. Van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010;18:605-12.
18. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011;19:515-42.
19. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471-8. (Pubitemid 39062707)
20. Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993;52:557-63. (Pubitemid 23246656)
21. Dieppe P. Subchondral bone should be the main target for the treatment of pain and disease progression in osteoarthritis. Osteoarthritis Cartilage 1999;7:325-6. (Pubitemid 29244113)
22. Kraus VB, McDaniel G, Worrell TW, Feng S, Vail TP, Varju G, et al. Association of bone scintigraphic abnormalities with knee malalignment and pain. Ann Rheum Dis 2009;68:1673-9.
23. Kinds MB, Marijnissen AC, Viergever MA, Emans PJ, Lafeber FP, Welsing PM. Identifying phenotypes of knee osteoarthritis by separate quantitative radiographic features may improve patient selection for more targeted treatment. J Rheumatol 2013;40:891-902.
24. Karsdal MA, Bay-Jensen AC, Lories RJ, Abramson S, Spector T, Pastoureau P, et al. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? Ann Rheum Dis 2014;73:336-48.
25. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
26. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-502.
27. Addison S, Coleman RE, Feng S, McDaniel G, Kraus VB. Whole-body bone scintigraphy provides a measure of the totalbody burden of osteoarthritis for the purpose of systemic biomarker validation. Arthritis Rheum 2009;60:3366-73.
28. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15. (Pubitemid 32823562)
29. Bay-Jensen AC, Andersen TL, Charni-Ben Tabassi N, Kristensen PW, Kjaersgaard-Andersen P, Sandell L, et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage 2008;16:615-23. (Pubitemid 351545558)
30. Kraus VB, Kepler TB, Stabler T, Renner J, Jordan J. First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis. PloS One 2010;5:e9739.
31. Henrotin Y, Pesesse L, Sanchez C. Subchondral bone and osteoarthritis: biological and cellular aspects. Osteoporos Int 2012;23:847-51.
32. Castaneda S, Roman-Blas JA, Largo R, Herrero-Beaumont G. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol 2012;83:315-23.
33. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 2008;16:638-46.
34. Hunter DJ, Hart D, Snieder H, Bettica P, Swaminathan R, Spector TD. Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxford) 2003;42:1311-6. (Pubitemid 37407022)
35. Hunter DJ, Spector TD. The role of bone metabolism in osteoarthritis. Curr Rheumatol Rep 2003;5:15-9.
36. Rogers J, Shepstone L, Dieppe P. Is osteoarthritis a systemic disorder of bone? Arthritis Rheum 2004;50:452-7. (Pubitemid 38198829)
37. Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998;102:2115-25. (Pubitemid 29018818)
38. McCrae F, Shouls J, Dieppe P, Watt I. Scintigraphic assessment of osteoarthritis of the knee joint. Ann Rheum Dis 1992;51:938-42.
39. McCarthy C, Cushnaghan J, Dieppe P. The predictive role of scintigraphy in radiographic osteoarthritis of the hand. Osteoarthritis Cartilage 1994;2:25-8. (Pubitemid 24159677)
40. Hamilton-Wood C, Hollingworth P, Dieppe P, Ackroyd C, Watt I. The painful swollen sterno-clavicular joint. Br J Radiol 1985;58:941-5. (Pubitemid 16215275)
41. Malmud LS, Charkes ND. Bone scanning: principles, technique and interpretation. Clin Orthop Rel Res 1975;107:112-22.
42. Roelofs AJ, Stewart CA, Sun S, Blazewska KM, Kashemirov BA, McKenna CE, et al. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 2012;27:835-47.
43. Kraus VB, Feng S, Wang S, White S, Ainslie M, Brett A, et al. Trabecular morphometry by fractal signature analysis is a novel marker of osteoarthritis progression. Arthritis Rheum 2009;60:3711-22.
44. Kraus VB, Feng S, Wang S, White S, Ainslie M, Graverand MP, et al. Subchondral bone trabecular integrity predicts and changes concurrently with radiographic and magnetic resonance imaging-determined knee osteoarthritis progression. Arthritis Rheum 2013;65:1812-21.
45. Ogawa K, Mukai T, Inoue Y, Ono M, Saji H. Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med 2006;47:2042-7. (Pubitemid 47544992)
46. Van Spil WE, Drossaers-Bakker KW, Lafeber FP. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis 2013;72:29-36.
47. Lohmander LS, Eyre D. Biochemical markers as surrogate end points of joint disease. In: Reid DM, Miller CG, editors. Clinical trials in rheumatoid arthritis and osteoarthritis. London: Springer; 2008. p. 249-74.
48. Gelse K, Soder S, Eger W, Diemtar T, Aigner T. Osteophyte development-molecular characterization of differentiation stages. Osteoarthritis Cartilage 2003;11:141-8. (Pubitemid 36221650)
49. Byrjalsen I, Leeming DJ, Qvist P, Christiansen C, Karsdal MA. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 2008;19:339-48. (Pubitemid 351199183)
50. Karsdal MA, Byrjalsen I, Leeming DJ, Delmas PD, Christiansen C. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int 2008;19:1355-61. Skin Diseases Skin Diseases